Company Focus

Obstructive sleep apnea (OSA) is a condition where sufferers stop breathing repeatedly during sleep, which causes daytime sleepiness and other long-term co-morbid complications. Approximately 10% of the general population suffer from this condition.

Current treatment options for OSA, such as Continuous Positive Airways Pressure (CPAP) and Mandibular Advancement Devices (MAD) are uncomfortable and as a result approximately 50% of patients do not use them long-term. Furthermore, current surgical procedures for OSA are expensive. New, cost effective, treatment options are require to successfully treat a larger proportion of OSA sufferers.

Our Technology

Respiosa is a simple, cost effective, minimally invasive surgically implanted solution to provide optimal therapy for tongue-based OSA. Respiosa prevents the tongue from collapsing into the airway when patients sleep on their backs.

The Respiosa implant is implanted under local anesthetic in a simple 30 minute procedure and adjusted to therapeutic levels approximately 2-4 weeks after implantation. There are only low levels of pain associated with the recovery from this procedure. The implant is permanent and well tolerated. Since Respiosa is natural and unobtrusive, patients don’t feel the implant, or interact with it, thus adherence is not an issue.

News from Respiosa


Respiosa, an NLC venture, will help people with obstructive sleep apnea through a revolutionary implant Obstructive sleep apnea (OSA) is a condition where people stop

Read More »